Metadate Er

Narcolepsy, Attention Deficit Hyperactivity Disorder
Treatment
20 Active Studies for Metadate Er

What is Metadate Er

MethylphenidateThe Generic name of this drug
Treatment SummaryMethylphenidate is a medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. It is sold under the brand names Ritalin, Concerta, or Biphentin. Methylphenidate works by increasing the levels of dopamine and norepinephrine in the brain, which helps to improve focus, reduce impulsivity and hyperactivity, and increase cognitive function. Long-term studies have shown that methylphenidate is a safe and effective treatment for ADHD. It comes in both immediate-release and long-acting forms so that it can be taken once-daily for up
Methylphenidate Hydrochlorideis the brand name
image of different drug pills on a surface
Metadate Er Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Methylphenidate Hydrochloride
Methylphenidate
1955
490

Effectiveness

How Metadate Er Affects PatientsMethylphenidate is a combination of two forms of the same drug, one of which is more active than the other. It works by attaching to protein sites in certain parts of the brain, especially in an area that plays a role in Attention Deficit Hyperactivity Disorder (ADHD). In animal studies, methylphenidate was shown to increase movement and cause certain behaviors.
How Metadate Er works in the bodyMethylphenidate helps to treat Attention Deficit Hyperactivity Disorder (ADHD) by increasing the presence of norepinephrine and dopamine in the brain. This helps to improve focus and attention, while also reducing impulsivity and movement. Research has shown that methylphenidate works by activating alpha-1 adrenergic receptor activity and overcoming any abnormalities in the dopamine transporter gene, D4 receptor gene, and D2 receptor gene.

When to interrupt dosage

The recommended measure of Metadate Er is contingent upon the given situation. The quantity of dosage is subject to the technique of delivery outlined in the table beneath.
Condition
Dosage
Administration
Attention Deficit Hyperactivity Disorder
20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg
, Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Transdermal, Patch, Patch - Transdermal, Suspension, extended release, Suspension, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Narcolepsy
20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg
, Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Transdermal, Patch, Patch - Transdermal, Suspension, extended release, Suspension, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Warnings

Metadate Er has fourteen contraindications and should not be taken concurrently with the ailments outlined in the table below.Metadate Er Contraindications
Condition
Risk Level
Notes
advanced arteriosclerosis
Do Not Combine
Gilles de la Tourette syndrome
Do Not Combine
Thyrotoxicosis
Do Not Combine
Pulse Frequency
Do Not Combine
Open-angle glaucoma
Do Not Combine
Hypertensive disease
Do Not Combine
Pulse Frequency
Do Not Combine
Tension
Do Not Combine
Generalized Anxiety Disorder
Do Not Combine
symptomatic cardiovascular disease
Do Not Combine
Gilles de la Tourette's Syndrome
Do Not Combine
Pheochromocytomas
Do Not Combine
Tic, Motor
Do Not Combine
Agitation
Do Not Combine
There are 20 known major drug interactions with Metadate Er.
Common Metadate Er Drug Interactions
Drug Name
Risk Level
Description
Desflurane
Major
Methylphenidate may increase the hypertensive activities of Desflurane.
Diethyl ether
Major
Methylphenidate may increase the hypertensive activities of Diethyl ether.
Enflurane
Major
Methylphenidate may increase the hypertensive activities of Enflurane.
Halothane
Major
Methylphenidate may increase the hypertensive activities of Halothane.
Isoflurane
Major
Methylphenidate may increase the hypertensive activities of Isoflurane.
Metadate Er Toxicity & Overdose RiskOverdosing on methadone may lead to vomiting, restlessness, shaking, reflex over-sensitivity, muscle twitching, seizures that can lead to unconsciousness, euphoria, confusion, hallucinations, delirium, sweating, flushing, a headache, high fever, rapid heart rate, irregular heartbeats, high blood pressure, enlarged pupils, and dry mouth. The lowest toxic dose in mice has been found to be 190mg/kg when taken orally.
image of a doctor in a lab doing drug, clinical research

Metadate Er Novel Uses: Which Conditions Have a Clinical Trial Featuring Metadate Er?

84 active clinical trials are presently underway to assess the utility of Metadate ER in the management of Attention Deficit Hyperactivity Disorder.
Condition
Clinical Trials
Trial Phases
Attention Deficit Hyperactivity Disorder
71 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1
Narcolepsy
10 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4, Phase 1

Metadate Er Reviews: What are patients saying about Metadate Er?

5Patient Review
1/2/2012
Metadate Er for Attention Deficit Disorder with Hyperactivity
I took this treatment for approximately one year. I found that it caused mood disturbances, depression, loss of appetite, headaches and stomach aches. Additionally, when I increased the dose I experienced agiation. Overall, I did not find it to be very helpful for ADHD symptoms.
4.7Patient Review
11/12/2009
Metadate Er for Attention Deficit Disorder with Hyperactivity
I was prescribed this for possible adult ADD and it made my mood swings much worse. I would definitely not recommend it to others who are struggling with a similar issue.
4Patient Review
1/28/2017
Metadate Er for Attention Deficit Disorder with Hyperactivity
This medication has been a lifesaver for my 16-year-old daughter. She used to have severe outbursts of anger, but since we switched her to metadate, they have decreased significantly. We recently increased her dose to 70 mg of extended release each morning, but it seems like the rages are starting to come back; so now we're also trying guanfacine in the afternoon.
3Patient Review
5/7/2008
Metadate Er for Attention Deficit Disorder with Hyperactivity
2.7Patient Review
9/2/2008
Metadate Er for Attention Deficit Disorder with Hyperactivity
I was prescribed this medicine recently, and it seems to be helping me.
2Patient Review
2/6/2011
Metadate Er for Attention Deficit Disorder with Hyperactivity
I've been using this medication for a while now and it definitely helps me stay focused. If I don't take it, I can tell the difference in my concentration level.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about metadate er

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Metadate CD and Metadate ER?

"The once-a-day Metadate CD capsule has biphasic release, with a quick release of methylphenidate at first, followed by a continuous-release phase. Metadate ER, a tablet taken two to three times per day, can be adjusted so that midday doses are no longer necessary."

Answered by AI

Is methylphenidate ER the same as Adderall?

"Both Adderall and Ritalin are central nervous system stimulants used to treat attention deficit hyperactivity disorder, though Ritalin is milder in effect."

Answered by AI

What is Metadate ER used for?

"Medate ER is a drug used to manage the symptoms of Attention Deficit Hyperactivity Disorder and Narcolepsy. It can be used by itself of with other drugs, and is classified as a stimulant and ADHD agent."

Answered by AI

Is metadate the same as Ritalin?

"The active ingredient in Metadate CD is also found in medications like Ritalin and Daytrana, which may improve focus, and decrease impulsivity and hyperactive behavior in some patients with the condition."

Answered by AI

Clinical Trials for Metadate Er

Have you considered Metadate Er clinical trials? We made a collection of clinical trials featuring Metadate Er, we think they might fit your search criteria.
Have you considered Metadate Er clinical trials? We made a collection of clinical trials featuring Metadate Er, we think they might fit your search criteria.
Have you considered Metadate Er clinical trials? We made a collection of clinical trials featuring Metadate Er, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top